Literature DB >> 22789539

Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming.

Yoichiro Mitsuishi1, Keiko Taguchi, Yukie Kawatani, Tatsuhiro Shibata, Toshihiro Nukiwa, Hiroyuki Aburatani, Masayuki Yamamoto, Hozumi Motohashi.   

Abstract

Cancer cells consume large quantities of nutrients and maintain high levels of anabolism. Recent studies revealed that various oncogenic pathways are involved in modulation of metabolism. Nrf2, a key regulator for the maintenance of redox homeostasis, has been shown to contribute to malignant phenotypes of cancers including aggressive proliferation. However, the mechanisms with which Nrf2 accelerates proliferation are not fully understood. Here, we show that Nrf2 redirects glucose and glutamine into anabolic pathways, especially under the sustained activation of PI3K-Akt signaling. The active PI3K-Akt pathway augments the nuclear accumulation of Nrf2 and enables Nrf2 to promote metabolic activities that support cell proliferation in addition to enhancing cytoprotection. The functional expansion of Nrf2 reinforces the metabolic reprogramming triggered by proliferative signals.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22789539     DOI: 10.1016/j.ccr.2012.05.016

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  501 in total

1.  Heme oxygenase promotes B-Raf-dependent melanosphere formation.

Authors:  Kimberly J Jasmer; Jie Hou; Philip Mannino; Jianlin Cheng; Mark Hannink
Journal:  Pigment Cell Melanoma Res       Date:  2020-07-09       Impact factor: 4.693

Review 2.  Metabolic Dependencies in RAS-Driven Cancers.

Authors:  Alec C Kimmelman
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

Review 3.  The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases.

Authors:  Prashant Deshmukh; Sruthi Unni; Gopinatha Krishnappa; Balasundaram Padmanabhan
Journal:  Biophys Rev       Date:  2016-12-06

4.  Cancer-derived mutations in KEAP1 impair NRF2 degradation but not ubiquitination.

Authors:  Bridgid E Hast; Erica W Cloer; Dennis Goldfarb; Heng Li; Priscila F Siesser; Feng Yan; Vonn Walter; Ning Zheng; D Neil Hayes; Michael B Major
Journal:  Cancer Res       Date:  2013-12-09       Impact factor: 12.701

Review 5.  Modulation of oxidative stress as an anticancer strategy.

Authors:  Chiara Gorrini; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2013-12       Impact factor: 84.694

6.  Anti-inflammatory activity of Barleria lupulina: Identification of active compounds that activate the Nrf2 cell defense pathway, organize cortical actin, reduce stress fibers, and improve cell junctions in microvascular endothelial cells.

Authors:  Donald R Senger; Mien V Hoang; Ki Hyun Kim; Chunshun Li; Shugeng Cao
Journal:  J Ethnopharmacol       Date:  2016-09-20       Impact factor: 4.360

7.  Comparison of Hepatic NRF2 and Aryl Hydrocarbon Receptor Binding in 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Treated Mice Demonstrates NRF2-Independent PKM2 Induction.

Authors:  Rance Nault; Claire M Doskey; Kelly A Fader; Cheryl E Rockwell; Tim Zacharewski
Journal:  Mol Pharmacol       Date:  2018-05-11       Impact factor: 4.436

Review 8.  Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance.

Authors:  S Dalleau; M Baradat; F Guéraud; L Huc
Journal:  Cell Death Differ       Date:  2013-10-04       Impact factor: 15.828

9.  Arl4c expression in colorectal and lung cancers promotes tumorigenesis and may represent a novel therapeutic target.

Authors:  S Fujii; S Matsumoto; S Nojima; E Morii; A Kikuchi
Journal:  Oncogene       Date:  2014-12-08       Impact factor: 9.867

10.  Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2.

Authors:  Liam Baird; Takafumi Suzuki; Yushi Takahashi; Eiji Hishinuma; Daisuke Saigusa; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2020-10-26       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.